1 - 3 June, 2027
Congress CenterBasel Switzerland Michael LukeschCEO at Valanx BiotechSpeaker
Profile
Michael Lukesch is the Founder and CEO of VALANX Biotech, a Vienna-based biotechnology company pioneering next-generation antibody-drug conjugates which he founded after his doctoral studies in Chemistry and Biotechnology at the Graz University of Technology. The company's GoldenSite(TM) technology allows exploration of previously unattainable conjugation sites via the latest generation of synthetic amino acids, enabling next-generation antibody and small-format conjugates. The company is pioneering its technology via its first asset, VLX-ADC-001 intended for treatment of triple-negative-breast cancer.
Agenda Sessions
Finding the Golden Site: How Synthetic Amino Acids and Third-generation Click-chemistry Enable the Next Generation of Protein Conjugates
, 14:25View Session